Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #680

    Done

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #681

      ok, curious if they will answer that

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #682

        Both CHRYSALIS/Amivantamab and the GEN1042 trials had their Estimated Primary Completion Date extended https://clinicaltrials.gov/ct2/history/NCT02609776?A=54&B=55&C=merged#StudyPageTop .https://clinicaltrials.gov/ct2/history/NCT04083599?A=3&B=4&C=merged#StudyPageTop which is a similar situation where i wonder if that is a good or a bad thing

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #683

          In this case primary completion and completion is not changed, so they are probably not stopping the trial.

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #684

            Andrew skriver SeaGen styrer dette studie, så ikke meget held der !

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #685

              Andrew writes that it is SeaGen that runs this study - so no luck there

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #686

                Such impressive deals on preclinical programs:

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #687

                  Just a moment...

                  favicon

                  (www.firstwordpharma.com)

                  1 Reply Last reply
                  0
                  • M Offline
                    M Offline
                    martinicph
                    wrote on sidst redigeret af
                    #688

                    Man kunne skrive til, [email protected]. Måske de svarer lige så hurtigt som Andrew. 🙂

                    1 Reply Last reply
                    0
                    • troldmandenT Offline
                      troldmandenT Offline
                      troldmanden
                      wrote on sidst redigeret af
                      #689

                      Når et studie standses så tidligt før tid så er det hvis mere reglen end undtagelsen det er dårligt nyt. Så vi skal ud i undtagelsen her hvis det er.... Der bør relativt hurtigt komme meddelelse med begrundelse

                      1 Reply Last reply
                      0
                      • D Offline
                        D Offline
                        deleted-user
                        wrote on sidst redigeret af
                        #690

                        Er studiet ikke forsat aktivt og rekruttering stoppet?

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #691

                          Jo - så helt galt er det ikke

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #692

                            Hvis der var alvorlige AE ville de jo ikke fortsætte med at behandle dem, der er rekrutteret.

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #693

                              Det er nok snarere på effektsiden at hunden ligger begravet.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #694

                                Or maybe just at stop of recruitment until this have been decided:

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #695

                                  The safety run-in period will evaluate the safety of a weekly schedule. The highest dose level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisot

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #696

                                    tumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is considered safe and tolerable in the safety run-in period.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #697

                                      that could also be possible, hadn't thought about that

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #698

                                        AbbVie routinely hiked prices for Humira, Imbruvica and abused patents to extend monopoly: congressional report https://www.fiercepharma.com/pharma/abbvie-repeatedly-raised-prices-for-humira-imbruvica-and-abused-u-s-patent-system-to-extend

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #699

                                          I don't think we have to worry that epcoritamab will be sold too cheap with Abbvie as partner...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger